Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Renal Drug Excretion: Glomerular Filtration01:02

Renal Drug Excretion: Glomerular Filtration

The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intestinal Smooth Muscle Macrophages: Linking the ENS and CNS in Parkinson's Disease.

Gastroenterology·2026
Same author

Validation of Family Medicine Point-of-Care Ultrasound Screening (POCUS) for Abdominal Aortic Aneurysm.

Journal of the American Board of Family Medicine : JABFM·2026
Same author

Neurogastroenterology and Motility: Toward New Horizons in 2026.

Neurogastroenterology and motility·2026
Same author

Front line child welfare perspectives on the utility and implementation of intensive family preservation services.

Children and youth services review·2026
Same author

Profiling the Enteric Nervous System.

Gastroenterology·2025
Same author

Microbiota Transplantation - It's a Match and a Mismatch.

Gastroenterology·2025

Related Experiment Video

Updated: Jul 12, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.

Murray Epstein1, Elizabeth Leary, Rachel Laskey

  • 1University of Miami School of Medicine, Miami, FL 33125, USA. m.epstein@miami.edu

Journal of the Cardiometabolic Syndrome
|September 6, 2007
PubMed
Summary

Atorvastatin did not affect kidney function markers in postmenopausal women with osteopenia and mild dyslipidemia. This study found no changes in serum creatinine, cystatin C, or other renal function indicators after one year of treatment.

Related Experiment Videos

Last Updated: Jul 12, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

Area of Science:

  • Nephrology
  • Pharmacology
  • Endocrinology

Background:

  • Osteopenia and mild dyslipidemia are common in postmenopausal women.
  • Statins, like atorvastatin, are widely used for dyslipidemia.
  • The impact of atorvastatin on renal function requires evaluation in specific populations.

Purpose of the Study:

  • To assess the effect of atorvastatin on renal function biomarkers.
  • To evaluate potential renal tubular and glomerular dysfunction induced by atorvastatin.
  • To determine if atorvastatin influences protein reabsorption or glomerular filtration rate.

Main Methods:

  • A 1-year randomized, placebo-controlled study.
  • Participants: Osteopenic postmenopausal women with mild dyslipidemia.
  • Interventions: Atorvastatin 20 mg, atorvastatin 80 mg, or placebo.
  • Assessments: Serum creatinine, cystatin C, urine N-acetyl-beta-D-glucosaminidase, urine and serum beta2-microglobulin, urine albumin.

Main Results:

  • Serum creatinine levels showed no significant differences across all treatment groups.
  • Cystatin C levels remained stable throughout the study period in all groups.
  • No significant alterations were observed in other renal function markers (urine N-acetyl-beta-D-glucosaminidase, beta2-microglobulin, urine albumin) between atorvastatin and placebo groups.
  • Neither moderate nor high doses of atorvastatin impacted glomerular or renal tubular function markers.

Conclusions:

  • Atorvastatin, even at high doses, does not appear to negatively affect renal function in osteopenic postmenopausal women with mild dyslipidemia.
  • The drug does not interfere with renal tubular protein reabsorption or cause tubular dysfunction.
  • Atorvastatin treatment for one year did not alter the glomerular filtration rate in this patient cohort.